F182112 + CD38

F182112 + CD38 is an investigational combination therapy being evaluated for the treatment of relapsed or refractory multiple myeloma (RRMM). F182112 is a humanized bispecific antibody developed by Shandong New Time Pharmaceutical (a subsidiary of Lunan Pharmaceutical Group) that targets B-cell maturation antigen (BCMA) on myeloma cells and the CD3 epsilon subunit on T cells, thereby facilitating T-cell mediated cytotoxicity against tumor cells. The combination regimen involves the administration of F182112 alongside a CD38-targeting monoclonal antibody (such as daratumumab). This dual-antigen targeting approach (BCMA and CD38) is intended to enhance anti-tumor efficacy and overcome resistance in patients who have previously failed standard-of-care treatments, including proteasome inhibitors and immunomodulatory drugs (IMiDs). The regimen is currently being studied in Phase II clinical trials (e.g., NCT07312188).

Other names

F182112 plus CD38 antibodyF-182112 plus CD38 antibodyF 182112 plus CD38 antibodyF182112 and CD38 antibodyF-182112 and CD38 antibodyF 182112 and CD38 antibody